Mastoparan (trifluoroacetate salt)
目录号 : GC47601
A neuropeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Mastoparan is a mast cell degranulating peptide originally isolated from Vespid wasp venom.1 It promotes degranulation by increasing GTPase activity for Gi and Go signaling independent of G protein-coupled receptor binding.2,3 Mastoparan also binds calmodulin (Kd = 0.3 nM) and inhibits the calmodulin-induced activation of phosphodiesterase (IC50 = 0.02 µM).4,5 In vitro, mastoparan was effective in killing leukemia, myeloma, and breast cancer cells (IC50s = 8-9.2, 11, and 20-24 µM, respectively).6 It worked synergistically with gemcitabine in a mouse model of mammary carcinoma.6
1.Hirai, Y., Yashuhara, T., Yoshida, H., et al.A new mast cell degranulating peptide "mastoparan" in the venom of Vespula lewisiiChem. Pharm. Bull. (Tokyo)27(8)1942-1944(1979) 2.Higashijima, T., Uzu, S., Nakajima, T., et al.Mastoparan, a peptide toxin from wasp venom, mimics receptors by activating GTP-binding regulatory proteins (G proteins)J. Biol. Chem.263(14)6491-6494(1988) 3.Higashijima, T., Burnier, J., and Ross, E.M.Regulation of Gi and Go by mastoparan, related amphiphilic peptides, and hydrophobic amines. Mechanism and structural determinants of activityJ. Biol. Chem.265(24)14176-14186(1990) 4.Malencik, D.A., and Anderson, S.R.High affinity binding of the mastoparans by calmodulinBiochem. Biophys. Res. Commun.114(1)50-56(1983) 5.Barnette, M.S., Daly, R., and Weiss, B.Inhibition of calmodulin activity by insect venom peptidesBiochem. Pharmacol.32(19)2929-2933(1983) 6.Hilchie, A.L., Sharon, A.J., Haney, E.F., et al.Mastoparan is a membranolytic anti-cancer peptide that works synergistically with gemcitabine in a mouse model of mammary carcinomaBiochim Biophys. Acta.1858(12)3195-3204(2016)
| Cas No. | N/A | SDF | |
| Canonical SMILES | O=C(N[C@@H]([C@@H](C)CC)C(N[C@H](C(N)=O)CC(C)C)=O)[C@H](CCCCN)NC([C@H](CCCCN)NC([C@H](C)NC([C@H](CC(C)C)NC([C@H](C)NC([C@H](C)NC([C@H](CC(C)C)NC([C@H](C)NC([C@H](CCCCN)NC([C@H](CC(C)C)NC([C@H](CC(N)=O)NC([C@@H](N)[C@@H](C)CC)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.FC(F)(C(O)=O)F | ||
| 分子式 | C70H131N19O15.XCF3COOH | 分子量 | 1478.9 |
| 溶解度 | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml,Ethanol:PBS (pH 7.2) (1:3): 0.25 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.6762 mL | 3.3809 mL | 6.7618 mL |
| 5 mM | 0.1352 mL | 0.6762 mL | 1.3524 mL |
| 10 mM | 0.0676 mL | 0.3381 mL | 0.6762 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet